✦ LIBER ✦

PP1. Resource implications of paclitaxel/cisplatinum versus cyclophosphamide/cisplatinum in the treatment of advanced ovarian cancer.

✍ Scribed by I Adriaenssen; M Piccart; JA Roy; G Hoctin Boes

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose cyclophosphamide followed by c

✍ Richard Osborne; Barrie Evans; Chris Gallagher; Christine Wood; Maurice Slevin; 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 487 KB

Efficacy of paclitaxel in combination wi

✍ Topuz, E.; Aydiner, A.; Eralp, Y.; Saip, P.; Tas, F.; Salihoglu, Y.; Berkman, S. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 345 KB

OP2. Cost-effectiveness analysis of pacl

✍ K Berger; T Szucs 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Phase III trial of The Japanese Urologic

✍ Akio Maru; Hideyuki Akaza; Shigeo Isaka; Kenkichi Koiso; Toshihiko Kotake; Toyoh 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 489 KB

Implications of BRCA1 and BRCA2 mutation

✍ Tan, David S.P.; Yap, Timothy A.; Hutka, Margaret; Roxburgh, Patricia; Ang, Jooe 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 246 KB

An economic analysis of dose dense weekl

✍ Heather J. Dalton; Xinhua Yu; Lilian Hu; Daniel S. Kapp; Ivor Benjamin; Bradley 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 558 KB